NCT06749730

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

A Prospective, Single Arm Study of Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (estimated)
• Sponsor: Henan Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of BTC in China.

Conditions

• Unresectable Biliary Tract Carcinoma

Interventions

Type	Name	Description
DRUG	Adebrelimab	adepelizumab ,1200mg, q3w
DRUG	Apatinib	apatinib，250mg，QD
DRUG	gemcitabine and cisplatin	cisplatin 25mg/m2，gemcitabine 1000mg/m2 d1,d8，q3w

Timeline

• Start date: 2024-04-01
• Primary completion: 2026-12-01
• Completion: 2027-06-01
• First posted: 2024-12-27
• Last updated: 2024-12-27

Locations

1 site across 1 country: China